Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
3320.HK Stock Summary
Top 10 Correlated ETFs
3320.HK
In the News
3320.HK Financial details
Company Rating
Strong Buy
Market Cap
32.29B
Income
8.52B
Revenue
515.36B
Book val./share
8.02
Cash/share
6.22
Dividend
0.16
Dividend %
3.07%
Employees
71K
Optionable
No
Shortable
Yes
Earnings
26 Mar 2024
P/E
4.18
Forward P/E
5.56
PEG
0.33
P/S
0.13
P/B
0.66
P/C
0.8
P/FCF
3.59
Quick Ratio
0.38
Current Ratio
1.25
Debt / Equity
1.78
LT Debt / Equity
0.13
-
-
EPS (TTM)
1.35
EPS next Y
0.9
EPS next Q
-
EPS this Y
10%
EPS next Y
-33.11%
EPS next 5Y
-33.11%
EPS last 5Y
0.62%
Revenue last 5Y
6.02%
Revenue Q/Q
8.22%
EPS Q/Q
166.67%
-
-
-
-
SMA20
-3.94%
SMA50
-1.73%
SMA100
5.35%
Inst Own
-
Inst Trans
-
ROA
3%
ROE
16%
ROC
0.13%
Gross Margin
15%
Oper. Margin
5%
Profit Margin
3%
Payout
12%
Shs Outstand
6.28B
Shs Float
1.69B
-
-
-
-
Target Price
-
52W Range
4.45-8.13
52W High
-37.5%
52W Low
+25%
RSI
44
Rel Volume
1.8
Avg Volume
8.23M
Volume
14.84M
Perf Week
-0.6%
Perf Month
2.46%
Perf Quarter
0.81%
Perf Half Y
-3.47%
-
-
-
-
Beta
0.363
-
-
Volatility
0.08%, 0.12%
Prev Close
-1.77%
Price
5
Change
-3.29%
3320.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 30.18 | 32.53 | 31.9 | 37.69 | 40.45 | |
Net income per share | 0.64 | 0.52 | 0.52 | 0.6 | 0.66 | |
Operating cash flow per share | 1.31 | 0.84 | 1 | 1.79 | 1.73 | |
Free cash flow per share | 1.07 | 0.51 | 0.65 | 1.32 | 1.2 | |
Cash per share | 7.11 | 3.63 | 8.33 | 5.94 | 5.18 | |
Book value per share | 6.26 | 6.48 | 7.4 | 8.11 | 7.89 | |
Tangible book value per share | 5.82 | 4.06 | 5.03 | 5.88 | 5.87 | |
Share holders equity per share | 6.26 | 6.48 | 7.4 | 8.11 | 7.89 | |
Interest debt per share | 10.53 | 9.01 | 9.65 | 13.43 | 10.98 | |
Market cap | 64.23B | 45.44B | 25.07B | 22.3B | 39.71B | |
Enterprise value | 110.81B | 82.82B | 65.98B | 79.56B | 82.58B | |
P/E ratio | 15.91 | 13.83 | 7.6 | 5.92 | 9.57 | |
Price to sales ratio | 0.34 | 0.22 | 0.13 | 0.09 | 0.16 | |
POCF ratio | 7.79 | 8.65 | 3.99 | 1.99 | 3.64 | |
PFCF ratio | 9.54 | 14.14 | 6.18 | 2.68 | 5.26 | |
P/B Ratio | 1.63 | 1.12 | 0.54 | 0.44 | 0.8 | |
PTB ratio | 1.63 | 1.12 | 0.54 | 0.44 | 0.8 | |
EV to sales | 0.58 | 0.41 | 0.33 | 0.34 | 0.33 | |
Enterprise value over EBITDA | 9.26 | 7.97 | 6.05 | 6.59 | 5.91 | |
EV to operating cash flow | 13.44 | 15.76 | 10.51 | 7.09 | 7.58 | |
EV to free cash flow | 16.46 | 25.77 | 16.26 | 9.57 | 10.95 | |
Earnings yield | 0.06 | 0.07 | 0.13 | 0.17 | 0.1 | |
Free cash flow yield | 0.1 | 0.07 | 0.16 | 0.37 | 0.19 | |
Debt to equity | 1.61 | 1.3 | 1.24 | 1.6 | 1.33 | |
Debt to assets | 0.36 | 0.28 | 0.27 | 0.33 | 0.27 | |
Net debt to EBITDA | 3.89 | 3.6 | 3.75 | 4.74 | 3.07 | |
Current ratio | 1.23 | 1.25 | 1.2 | 1.25 | 1.25 | |
Interest coverage | 3.55 | 2.16 | 2.68 | 3.41 | 3.79 | |
Income quality | 2.07 | 1.6 | 1.9 | 2.98 | 2.63 | |
Dividend Yield | 0.01 | 0.02 | 0.03 | 0.03 | 0.02 | |
Payout ratio | 0.17 | 0.25 | 0.21 | 0.2 | 0.23 | |
Sales general and administrative to revenue | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | |
Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Intangibles to total assets | 0.14 | 0.24 | 0.23 | 0.24 | 0.22 | |
Capex to operating cash flow | -0.18 | -0.39 | -0.35 | -0.26 | -0.31 | |
Capex to revenue | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
Capex to depreciation | -1 | -0.86 | -0.91 | -1.03 | -1.06 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 9.51 | 8.73 | 9.34 | 10.47 | 10.82 | |
ROIC | 0.08 | 0.06 | 0.06 | 0.05 | 0.07 | |
Return on tangible assets | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | |
Graham Net | -3.95 | -3.62 | -2.26 | -3.43 | -4.12 | |
Working capital | 23.91B | 26.27B | 24.49B | 35.29B | 34.13B | |
Tangible asset value | 36.6B | 25.52B | 31.6B | 36.94B | 36.86B | |
Net current asset value | 11.55B | 13.1B | 18.42B | 23.92B | 20.22B | |
Invested capital | 1.61 | 1.3 | 1.24 | 1.6 | 1.33 | |
Average receivables | 53.11B | 65.71B | 75.3B | 85.88B | 103.96B | |
Average payables | 40.87B | 34.51B | 30.35B | 34.48B | 38.73B | |
Average inventory | 21.47B | 21.93B | 23.46B | 27.14B | 29.7B | |
Days sales outstanding | 90.94 | 150.24 | 121.01 | 162.31 | 147.4 | |
Days payables outstanding | 93.22 | 63.15 | 67.78 | 68.4 | 67.43 | |
Days of inventory on hand | 50.77 | 47.83 | 53.37 | 53.8 | 50.46 | |
Receivables turnover | 4.01 | 2.43 | 3.02 | 2.25 | 2.48 | |
Payables turnover | 3.92 | 5.78 | 5.39 | 5.34 | 5.41 | |
Inventory turnover | 7.19 | 7.63 | 6.84 | 6.78 | 7.23 | |
ROE | 0.1 | 0.08 | 0.07 | 0.07 | 0.08 | |
Capex per share | -0.24 | -0.32 | -0.35 | -0.46 | -0.53 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2021-06-30 | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 18.22 | 19.47 | 20.01 | 20.44 | 22.12 | |
Net income per share | 0.39 | 0.21 | 0.48 | 0.18 | 0.48 | |
Operating cash flow per share | -0.33 | 2.12 | -0.7 | 2.43 | -0.88 | |
Free cash flow per share | -0.48 | 1.81 | -0.95 | 2.16 | -1.1 | |
Cash per share | 9.45 | 5.94 | 6.12 | 5.18 | 6.22 | |
Book value per share | 7.75 | 8.11 | 8.05 | 7.89 | 8.02 | |
Tangible book value per share | 5.5 | 5.88 | 5.86 | 5.87 | 6.29 | |
Share holders equity per share | 7.75 | 8.11 | 8.05 | 7.89 | 8.02 | |
Interest debt per share | 13.07 | 13.2 | 14.32 | 10.76 | 14.54 | |
Market cap | 30.41B | 22.3B | 33.49B | 39.71B | 42.85B | |
Enterprise value | 87.8B | 79.56B | 97.09B | 82.58B | 101.17B | |
P/E ratio | 3.12 | 4.19 | 2.77 | 8.84 | 3.53 | |
Price to sales ratio | 0.27 | 0.18 | 0.27 | 0.31 | 0.31 | |
POCF ratio | -14.53 | 1.68 | -7.67 | 2.6 | -7.79 | |
PFCF ratio | -10.01 | 1.96 | -5.58 | 2.93 | -6.2 | |
P/B Ratio | 0.62 | 0.44 | 0.66 | 0.8 | 0.85 | |
PTB ratio | 0.62 | 0.44 | 0.66 | 0.8 | 0.85 | |
EV to sales | 0.77 | 0.65 | 0.77 | 0.64 | 0.73 | |
Enterprise value over EBITDA | 12.96 | 15.02 | 11.8 | 14.4 | 11.56 | |
EV to operating cash flow | -41.95 | 5.98 | -22.22 | 5.41 | -18.4 | |
EV to free cash flow | -28.9 | 7.01 | -16.19 | 6.1 | -14.63 | |
Earnings yield | 0.08 | 0.06 | 0.09 | 0.03 | 0.07 | |
Free cash flow yield | -0.1 | 0.51 | -0.18 | 0.34 | -0.16 | |
Debt to equity | 1.66 | 1.6 | 1.75 | 1.33 | 1.78 | |
Debt to assets | 0.34 | 0.33 | 0.35 | 0.27 | 0.33 | |
Net debt to EBITDA | 8.47 | 10.81 | 7.73 | 7.48 | 6.66 | |
Current ratio | 1.21 | 1.25 | 1.27 | 1.25 | 1.26 | |
Interest coverage | 3.67 | 3.07 | 4.86 | 2.8 | 4.35 | |
Income quality | -0.86 | 10 | -1.44 | 13.6 | -1.81 | |
Dividend Yield | 0.02 | 0 | 0 | 0.02 | 0 | |
Payout ratio | 0.31 | 0 | 0 | 0.84 | 0 | |
Sales general and administrative to revenue | 0.02 | 0.03 | 0.02 | 0.03 | 0.02 | |
Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Intangibles to total assets | 0.21 | 0.24 | 0.22 | 0.22 | 0.2 | |
Capex to operating cash flow | 0.45 | -0.15 | 0.37 | -0.11 | 0.26 | |
Capex to revenue | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | |
Capex to depreciation | -0.69 | -1.34 | -1.02 | -1.11 | -0.83 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 8.22 | 6.22 | 9.34 | 5.63 | 9.34 | |
ROIC | 0.03 | 0.02 | 0.04 | 0.03 | 0.04 | |
Return on tangible assets | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | |
Graham Net | -2.77 | -3.43 | -3.96 | -4.12 | -4.87 | |
Working capital | 30.09B | 35.29B | 40.17B | 34.13B | 41.2B | |
Tangible asset value | 34.53B | 36.94B | 36.84B | 36.86B | 39.49B | |
Net current asset value | 20.87B | 23.92B | 23.73B | 20.22B | 23.59B | |
Invested capital | 1.66 | 1.6 | 1.75 | 1.33 | 1.78 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 0 | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 62.28 | 77.48 | 81.55 | 71.93 | 77.98 | |
Days payables outstanding | 34.59 | 32.54 | 34.86 | 32.77 | 35.49 | |
Days of inventory on hand | 25.16 | 25.59 | 24.72 | 24.52 | 26.93 | |
Receivables turnover | 1.44 | 1.16 | 1.1 | 1.25 | 1.15 | |
Payables turnover | 2.6 | 2.77 | 2.58 | 2.75 | 2.54 | |
Inventory turnover | 3.58 | 3.52 | 3.64 | 3.67 | 3.34 | |
ROE | 0.05 | 0.03 | 0.06 | 0.02 | 0.06 | |
Capex per share | -0.15 | -0.31 | -0.26 | -0.27 | -0.23 |
3320.HK Frequently Asked Questions
What is China Resources Pharmaceutical Group Limited stock symbol ?
China Resources Pharmaceutical Group Limited is a HK stock and trading under the symbol 3320.HK
What is China Resources Pharmaceutical Group Limited stock quote today ?
China Resources Pharmaceutical Group Limited stock price is $5 today.
Is China Resources Pharmaceutical Group Limited stock public?
Yes, China Resources Pharmaceutical Group Limited is a publicly traded company.